Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Resveratrol and Increased Plasminogen Activator Inhibitor-1 Level

Doses used in studies

mg/day: 300 (median 300, IQR 300–300) — 1 study

Time to effect

Median: 3 months · IQR 3 months–3 months · Range 3 months–3 months — Reported in 1 of 1 study

1 of 1 paper

Higher dose of resveratrol elevated cardiovascular disease risk biomarker levels in overweight older adults - A pilot study.
- 2019-12-28
- RCT · n = 10
- Experimental gerontology 131
- - R T Mankowski
  - L You
  - T W Buford
  - C Leeuwenburgh
  - T M Manini
  - S Schneider
  - P Qiu
  - S D Anton
- PubMed: 31891746
- DOI: 10.1016/j.exger.2019.110821
5 Insights on
- Increased Plasminogen Activator Inhibitor-1 Level
- High evidence
- Elderly
Given no change in the CVD risk biomarkers in response to a lower dose
Effect
Neutral
Effect size
Small
Significant
No
Dose
300 mg/day